Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life
|
Jan 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia
|
Oct 2014
|
Blood
|
aplastic anemia
|
Cyclophosphamide in severe aplastic anemia?
|
Oct 2014
|
Blood
|
aplastic anemia
|
Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications
|
Oct 2017
|
Blood Advances
|
aplastic anemia
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
|
Nov 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes
|
Oct 2019
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
|
Oct 2017
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
|
Mar 2017
|
Blood Advances
|
acute myeloid leukemia (AML)
|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
|
Jul 2020
|
Blood Advances
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
|
Feb 2021
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|